Free tool
FAERS Monitor: Tracleer
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209279 or its brand name (Tracleer, Bosentan). Reports on generic versions are filed under their own applications.
Reports
10,091
Serious
8,557
85% of reports
Hospitalization
5,097
Death reported
3,159
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death1,885
- dyspnoea1,213
- pneumonia551
- fatigue452
- headache441
- pulmonary arterial hypertension438
- diarrhoea401
- nausea401
- condition aggravated376
- dizziness355
- malaise352
- vomiting314
- fluid retention310
- cough305
- fall303
Reports by year received
View as table
| Year | Reports |
|---|
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,068 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pulmonary arterial hypertensionSignal | 438 | 370.3 | 335.1 | 136,683 |
| fluid retentionSignal | 310 | 12.8 | 11.4 | 3,341 |
| deathSignal | 1,885 | 4.6 | 4.4 | 5,463 |
| dyspnoeaSignal | 1,213 | 4.5 | 4.2 | 3,351 |
| pneumoniaSignal | 551 | 3.6 | 3.3 | 1,022 |
| condition aggravatedSignal | 376 | 2.6 | 2.3 | 367 |
| coughSignal | 305 | 2.3 | 2.0 | 218 |
| fall | 303 | 1.9 | 1.7 | 130 |
| malaise | 352 | 1.7 | 1.5 | 97 |
| dizziness | 355 | 1.5 | 1.3 | 57 |
| headache | 441 | 1.5 | 1.3 | 67 |
| vomiting | 314 | 1.4 | 1.2 | 35 |
| diarrhoea | 401 | 1.3 | 1.2 | 27 |
| fatigue | 452 | 1.2 | 1.1 | 17 |
| nausea | 401 | 1.1 | 1.0 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.